tbuckley/cabot-search huggingface dataset:
CMET-33. PHASE II STUDY OF PALBOCICLIB IN BRAIN METASTASES HARBORING CDK PATHWAY ALTERATIONS
Authors: Priscilla Brastianos, Justine Cohen, Nancy Wang, Eudocia Lee, Jennifer Ligibel, Ugonma Chukwueke, Maura Keeley, Kevin Oh, Michael White, Elizabeth Gerstner, Tracy Batchelor, Donald Lawrence, David P Ryan, A John Iafrate, Anita Giobbie-Hurder, Keith Flaherty, Sandro Santagata, Scott Carter, Daniel Cahill, Ryan Sullivan
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Up to 25% of all cancer patients will develop brain metastases and prognosis remains poor. In preclinical work, we discovered that more than 50% brain metastases genomically diverge from primary tumors and harbor alterations in genes involved with cell cycle regulation. We thus initiated a phase II study to evaluate the efficacy and safety of the cyclin dependent kinase (CDK) 4/6 inhibitor, palbociclib, in patients with recurrent brain metastases with alterations in the CDK pathway (NCT02896335). METHODS The primary endpoint of the trial is the rate of intracranial benefit (defined as CR, PR, or SD, per RANO) at 8 weeks after the start of palbociclib. A Simon two-stage design was used to compare the rate of intracranial benefit for a null rate of 10% against an alternative of 30%. Fifteen patients were to be enrolled in the first stage. If fewer than 2 responders were observed, then the study would stop for insufficient evidence of efficacy. If 6 or more responders were observed among the total of 30, this treatment regimen would be considered worthy of further study. CSF, blood samples and tumor samples were collected to elucidate the genomic determinants of response to CDK inhibitors in the brain. RESULTS A total of 14 patients have been accrued (5 with breast cancer, 4 with melanoma, 3 esophageal and 2 with non-small cell lung cancer) thus far. One or more grade-3 or higher adverse events at least possibly related to treatment were seen in six (42%) patients, the majority being hematologic toxicities. At the time of the data analysis, eight (57%) patients had achieved intracranial benefit. Therefore, the study met primary endpoint. CONCLUSIONS In this unique, genomically-guided brain metastasis trial, we demonstrate that the CDK 4/6 inhibitor, palbociclib, is well-tolerated and has activity in patients with brain metastases.
Serum Albumin Level, but Not Nutritional Risk Index Predicts Outcomes in Acute Leukemia Patients after Allo-HSCT
Authors: Mikhail Yu. Drokov, Natalia N. Popova, Vera A. Vasilyeva, Ekaterina D. Mikhaltsova, Olga M. Koroleva, Zoya V. Konova, Anna A. Dmitrova, Olga S. Starikova, Ulyana V. Maslikova, Maria V. Dovydenko, Ekterina Usikova, Larisa A. Kuzmina, Elena N. Parovichnikova, Valery G. Savchenko
Journal: Blood (2019)
SCIDOT-24. INCREASING INDUCED NEURAL STEM CELL PERSISTENCE IN THE TUMOR RESECTION CAVITY
Authors: Hunter Bomba, Kevin Sheets, Abigail Carey-Ewend, Morgan Goetz, Juli Bago, Simon Khagi, Shawn Hingtgen
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma multiforme (GBM) is the most common primary brain cancer in adults. Afflicted patients have a median survival rate of only 15 months, and patient survival statistics have remained stagnant for over three decades. Current standard of care includes maximal safe tumor resection, chemotherapy, and radiation. Nevertheless, GBM is aggressive, making recurrence and deeper tumor infiltration inevitable. Neural stem cells transdifferentiated from a skin biopsy, i.e. induced neural stem cells (iNSCs), have the innate ability to home to tumors, and, when engineered with cytotoxic proteins, can actively kill cancer cells. However, direct injection of these cells into the hostile immune environment of the tumor resection cavity results in an accelerated clearance rate and therefore a shortened therapeutic window. To combat this clearance issue, we investigated the FDA-approved hemostatic matrix, Floseal, as a cell delivery platform to increase iNSC persistence. In vitro, SEM imaging showed homogeneous iNSC distribution throughout Floseal. Using our surgical resection model of GBM in mice, we delivered iNSCs into the post-surgical cavity in Floseal and by direct injection to model current clinical delivery strategies. Serial kinetic imaging showed that human iNSC persistence delivered into the cavity in Floseal persisted over 90 days, while cells directly injected into the brain parenchyma persist less than 20 days. When we investigated the impact on tumor kill, we found the increase in persistence increased survival of GBM-bearing mice more than 30 days compared to control cells. Light-sheet microscopy showed wild-type neural stem cells migrate into invasive GBM-8 tumors in the contralateral hemisphere, and we are now using this approach to validate the homing of iNSCs delivered via Floseal. Administration of iNSCs encapsulated in the biocompatible Floseal matrix offers a promising, clinically-translatable therapeutic strategy for GBM.
Post-Transplant Cyclophosphamide in Allogeneic Bone Marrow Transplantation for the Treatment of Benign Hematologic Diseases
Authors: Mark Leick, Bradley Hunter, Zachariah Defilipp, Bimalangshu Dey, Areej El-Jawahri, Matthew J. Frigault, Steven L McAfee, Thomas Spitzer, Paul V. O'Donnell, Yi-Bin Chen
Journal: Blood (2019)
Cathelicidin Antimicrobial Peptide Expression Is Inversely Associated with Absolute Neutrophil Counts in Pediatric HCT Recipients
Authors: Jos Domen, Hung-Wen Yeh, Nancy L Shreve, Lei Sun, Yongwu Li, Katrina D Walters, Jignesh Dalal, Rakesh K. Goyal
Journal: Blood (2019)
Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia
Authors: Bruno Fattizzo, Marc Michel, Laetitia Languille, Juri Giannotta, Henrik Frederiksen, Francesca Romana Mauro, Bernd Jilma, Elisa Lucchini, Andrea Patriarca, Francesco Zaja, Anita Hill, Sigbjorn Berentsen, Wilma Barcellini
Journal: Blood (2019)
The Extent of Neurosis
Authors: L. F. Donnan
Journal: BMJ (1947)

divisions-extractions, by which the whole varicose vein could be extirpated through incisions-rarely more than 1/4 to 1/3 in. (0.63-0.85 cm.) in length-at intervals along the vein, the sites for incision carefully selected in the standing patient and indelibly marked before operation.The incisions, Wiade parallel to the lines of tension of the skin, gape but little and do not require suLturing.Only very few ligations of severed veins are ever necessary, and perforating veins and tributaries can be divided and ligated or, if small, torn off flush with the deep fascia with- out the use of a vein enucleator.In some cases new varicose veins have appeared so soon after extirpation of the old as to raise inescapably the question of overloading in the deep veins and a new compensatory reflux through deep communicating veins, and the wisdom of severing all deep communications, if that were feasible.Here I take opportunity to record my indebtedness to Mr.
Challenging the Association of Marijuana Laws With Teen Marijuana Use
Authors: Eli Rapoport, Sarah A. Keim, Andrew Adesman
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi
Authors: Annalisa Chiappella, Monica Balzarotti, Chiara Monagheddu, Federica Cavallo, Maria Giuseppina Cabras, Manuela Zanni, Catello Califano, Francesca Re, Angela Giovanna Congiu, Paolo Corradini, Attilio Olivieri, Anna Marina Liberati, Stefano Volpetti, Mariagrazia Michieli, Alessandra Tucci, Monica Tani, Luca Nassi, Rita Mazza, Mattia Novo, Stefano A Pileri, Giovannino Ciccone, Umberto Vitolo
Journal: Blood (2019)
Rivaroxaban Reduces the Levels of Extracellular Vesicles in Patients with Venous Thromboembolism and Non-Valvular Atrial Fibrillation
Authors: Sarah Kelliher, Luisa Weiss, Paulina Szklanna, Karl Egan, Tadhg Prendiville, Eric Moran, Georgi Petrov, Alfonso Blanco, Aine Lennon, Sean Murphy, John Keaney, Fionnuala Ni Ainle, Patricia Maguire
Journal: Blood (2019)
COMP-15. MOLECULAR AND CLONAL EVOLUTION IN RECURRENT METASTATIC GLIOSARCOMA
Authors: Kevin Anderson, Aaron Tan, Jonathon Parkinson, Michael Back, Marina Kastela, Allison Newey, Janice Brewer, Helen Wheeler, Amanda Hudson, Samirkumar Amin, Kevin C Johnson, Floris Barthel, Roel Verhaak, Mustafa Khasraw
Journal: Neuro-Oncology (2019)

Abstract Gliosarcoma, a World Health Organization grade IV glioma, is a rare variant of glioblastoma (GBM) that contains distinct glial and mesenchymal components. Histologically, the glial component matches criteria for glioblastoma, and both components share genetic alterations common to GBM. Though GBM are known to strongly infiltrate surrounding tissue, extracranial metastases are rare, and the underlying mechanisms are still poorly understood. We present a rare case of a 37-year-old woman who was initially diagnosed with IDH wild-type gliosarcoma in the frontal lobe and later developed two local recurrences and extracranial metastases to the vertebral and pelvic bones. In order to understand the clonal relationships between four tumor instances and the origin of metastasis, we performed whole genome sequencing of the intracranial tumors and the tumor located in the right iliac bone. We compared mutational and copy number profiles and inferred tumor clonal phylogeny. The tumors harbored shared GBM alterations including TP53, NF1, and RB1 mutations and CDKN2A deletion. Comparisons of the metastatic to intracranial tumors highlighted a high similarity in molecular profiles, but contrasting evidence regarding the origin of the metastasis. The metastasis was most similar to the second recurrence with respect to mutational signatures, reflected in the activity of signatures associated with defective DNA mismatch repair not observed in the primary or first recurrent tumor. The metastasis was most similar to the first recurrence with respect to copy number profile; both samples displayed widespread amplifications indicative of whole genome doubling. Results of subclonal reconstruction suggested that the second recurrent and metastatic tumors originated from more than one clone and developed subclone-specific driver mutations. The branching phylogeny and copy number profiles suggest the metastasis was largely derived from the first recurrence. This is the first analysis of clonal evolution of extracranial metastasis in gliosarcoma and highlights alterations driving aggressive GBM progression.
Plasma and Dietary Linoleic Acid and 3-Year Risk of Type 2 Diabetes After Myocardial Infarction: A Prospective Analysis in the Alpha Omega Cohort
Authors: Kamalita Pertiwi, Anne J. Wanders, Marjolein C. Harbers, Leanne K. Küpers, Sabita S. Soedamah-Muthu, Janette de Goede, Peter L. Zock, Johanna M. Geleijnse
Journal: Diabetes Care (2019)

OBJECTIVE To study plasma and dietary linoleic acid (LA) in relation to type 2 diabetes risk in post–myocardial infarction (MI) patients. RESEARCH DESIGN AND METHODS We included 3,257 patients aged 60–80 years (80% male) with a median time since MI of 3.5 years from the Alpha Omega Cohort and who were initially free of type 2 diabetes. At baseline (2002–2006), plasma LA was measured in cholesteryl esters, and dietary LA was estimated with a 203-item food-frequency questionnaire. Incident type 2 diabetes was ascertained through self-reported physician diagnosis and medication use. Hazard ratios (with 95% CIs) were calculated by Cox regressions, in which dietary LA isocalorically replaced the sum of saturated (SFA) and trans fatty acids (TFA). RESULTS Mean ± SD circulating and dietary LA was 50.1 ± 4.9% and 5.9 ± 2.1% energy, respectively. Plasma and dietary LA were weakly correlated (Spearman r = 0.13, P &amp;lt; 0.001). During a median follow-up of 41 months, 171 patients developed type 2 diabetes. Plasma LA was inversely associated with type 2 diabetes risk (quintile [Q]5 vs. Q1: 0.44 [0.26, 0.75]; per 5%: 0.73 [0.62, 0.86]). Substitution of dietary LA for SFA+TFA showed no association with type 2 diabetes risk (Q5 vs. Q1: 0.78 [0.36, 1.72]; per 5% energy: 1.18 [0.59, 2.35]). Adjustment for markers of de novo lipogenesis attenuated plasma LA associations. CONCLUSIONS In our cohort of post-MI patients, plasma LA was inversely related to type 2 diabetes risk, whereas dietary LA was not related. Further research is needed to assess whether plasma LA indicates metabolic state rather than dietary LA in these patients.
Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis
Authors: Pallavi Mehta, Neha Yadav, Mohan Bhaarat, Sumeet Prakash Mirgh, Vishvdeep Khushoo, Shinto Francis Thekuddan, Narendra Agrawal, Rayaz Ahmed, Dinesh Bhurani
Journal: Blood (2019)
Early Diagnosis of Tuberculous Meningitis
Authors: D. Gairdner
Journal: BMJ (1947)

Many Russians in my care during the war, even those who had been wounded before capture, awaited their return home with extreme terror.Why ?I agree that social security, whatever it may mean, has tended to reduce effort for the reasons advanced by Dr. Crichton-Miller.Many economists suggest that the economic basis for this social security is crumbling, so we may soon see the next phase developing.-Iam, etc.,
Medicine and the Law
Authors: Louis J. Regan
Journal: New England Journal of Medicine (1954)

LEGAL medicine is frequently defined as the application of medical knowledge to the needs of justice. However, the subject can be viewed more precisely by separation into two major divisions. The first involves a physician's practice of his special skills in medicolegal investigations, and the second a legal evaluation of the physician's personal, ethical and professional conduct.The Physician in Medicolegal Investigations The first subdivision involves situations in which a physician acts objectively in applying special skills to the study of matter submitted and afterward reports on it or testifies to it. These situations include the practice of forensic pathology, . . .
Hydroxyurea Pharmacokinetic Profiles in Children Treated for Extreme Thrombocytosis after Total Pancreatectomy with Islet Cell Autotransplant Demonstrate Poor Absorption
Authors: Alexander A Boucher, Min Dong, Anu Marahatta, Adriane Hausfeld, Thad A. Howard, Jaimie D Nathan, Alexander A. Vinks, Patrick T. McGann, Russell E. Ware, Lori Luchtman-Jones
Journal: Blood (2019)
Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma
Authors: Changying Jiang, Rongjia Zhang, Shaojun Zhang, William Lee, Shengjian Huang, Yang Liu, Angela Leeming, Joseph Mitchell McIntosh, Preetesh Jain, Krystle Nomie, Linghua Wang, Michael L. Wang
Journal: Blood (2019)
Septicemia after Chemotherapy for Acute Lymphoblastic Leukemia: A Multicenter Study Chinese Children Cancer Group (CCCG)-ALL-2015
Authors: Chi Kong Li, Yiping Zhu, JingYan Tang, Xiuli Ju, Runming Jin, Ningling Wang, Yumei Chen, Hui Jiang, Shaoyan Hu, Hu Liu, Kaili Pan, Jiaoyang Cai, Yanjing Tang, Yingyi He, Rong Yang, Xiaowen Zhai, Lirong SUN, Yu Jie
Journal: Blood (2019)
Non-Myeloablative Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia: Graft-Versus-Host Disease Potentiates Graft-Versus-Leukemia Effect and Improves Overall Survival
Authors: Christopher J Pizzola, Kevin L Rakszawski, W. Christopher Ehmann, Witold B. Rybka, Baldeep Wirk, Seema Naik, Hong Zheng, Brook Silar, Gina Mackey, Shin Mineishi, Kentaro Minagawa, David F. Claxton
Journal: Blood (2019)
Core Biopsies Performed By Experienced Radiologists and Analysed By Expert Haemato-Pathologists Reliably Permit the Rapid and Safe Diagnosis of Lymphoproliferative Diseases and Negate the Need for Excisional Biopsy in Almost All Patients. Experience from 554 Sequential Core Biopsies from a Single Centre
Authors: Oliver C Cohen, Max Brodermann, Aoife Dervin, Simon Morley, Ian Proctor, Neel Raja, Kirit M. Ardeshna, William Townsend
Journal: Blood (2019)
Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells
Authors: Patrick P. Ng, Mehrdad Mobasher, Kitman S. Yeung, Andrew N. Hotson, Craig M. Hill, Antonett Madriaga, Trang P. Dao-Pick, Erik Verner, Dejan Radeski, Michael S. Khodadoust, Youn H. Kim, Richard A. Miller, Joseph J. Buggy, James W. Janc
Journal: Blood (2019)
CMET-15. SARCOPENIA INDEPENDENTLY AND STRONGLY PREDICTS SURVIVAL IN PATIENTS UNDERGOING SPINE SURGERY FOR METASTATIC TUMORS
Authors: Hesham Zakaria, Yamaan Saadeh, Darryl Lau, Zachary Pennington, Ali Ahmed, Ankush Chandra, Mohamed Macki, Ian Lee, Dean Chou, Paul Park, Daniel Sciubba, Victor Chang
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Predicting survival and surgical morbidity in patients with spinal metastases would help guide clinical decision making and stratify treatments between surgical intervention and palliative care. This multi-center retrospective cohort study evaluates whether the frailty/sarcopenia paradigm, as measured by psoas size, is predictive of survival in patients undergoing surgery for spinal metastasis. METHODS 271 patients from four institutes who had undergone surgery for spinal metastasis were identified. Morphometric measurements were taken of the psoas muscle at the L4 vertebral level &lt; 200d from surgery. Mortality hazard ratios were calculated using multivariate analysis, with variables included from past medical history, type and extent of tumor spread, type and intensity of surgery, and postoperative chemotherapy or radiation. RESULTS Psoas size was predictive of overall mortality; patients in the smallest tertile had shorter overall survival compared to the middle (OR 0.52, p&lt; 0.001) and largest tertile (OR 0.45, p&lt; 0.001). Psoas size predicted overall mortality more strongly than Tokuhashi score (OR 0.91, p= 0.010), Tomita score (OR 1.07, p= 0.04), and KPS (OR 0.99, p= 0.58). Psoas size was also predictive of 90-day survival; patients in the smallest tertile had shorter 90-day survival compared to the middle (OR 0.24, p= 0.003) and largest tertile (OR 0.16, p= 0.001). Psoas size predicted 90-day mortality more strongly than Tokuhashi score (OR 0.73, p= 0.002), Tomita score (OR 1.00, p= 0.92), and KPS (OR 0.98, p= 0.39). CONCLUSION In patients undergoing surgery for spine metastases, psoas size as a surrogate for frailty/sarcopenia predicts 90-day and overall mortality, independent of demographical, functional, oncological, and surgical characteristics. The sarcopenia/frailty paradigm is a stronger predictor of survival at these time points than the Tokuhashi score, Tomita score, and KPS. Psoas size can be used in clinical decision-making to select which patients with metastatic spine tumors are appropriate surgical candidates.
Doxycycline Combined with Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Patients with Mayo 2004 Stage II-III Light-Chain Amyloidosis: A Randomized Controlled Multicenter Study
Authors: Kaini Shen, Yujun Dong, Weijun Fu, Yu Wu, Zhongxia Huang, Yongqiang Wei, Chunrui Li, Chunyan Sun, Wenrong Huang, Huihan Wang, Congli Zhang, Huilei Miao, Lu Zhang, Xinxin Cao, Daobin Zhou, Jian Li
Journal: Blood (2019)
Long-term Oncological Outcomes from an Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL)
Authors: Muhammad Shamim Khan, Kawa Omar, Kamran Ahmed, Christine Gan, Mieke Van Hemelrijck, Rajesh Nair, Ramesh Thurairaja, Peter Rimington, Prokar Dasgupta
Journal: European Urology (2019)
Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials
Authors: Arafat Ali Farooqui, Humaira Sarfraz, Zunairah Shah, Muhammad Saad Farooqi, Maimoona Khan, Aqsa Ashraf, Ahmad Anjum, Talha Bin Farooq, Tanveer Shaukat, Ali Younas Khan, Madeeha Shafqat, Muhammad Junaid Tariq, Faiz Anwer
Journal: Blood (2019)
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
Authors: J. Wouter Jukema, Laurien E. Zijlstra, Deepak L. Bhatt, Vera A. Bittner, Rafael Diaz, Heinz Drexel, Shaun G. Goodman, Yong-Un Kim, Robert Pordy, Željko Reiner, Matthew T. Roe, Hung-Fat Tse, Pablo Carlos Montenegro Valdovinos, Harvey D. White, Andreas M. Zeiher, Michael Szarek, Gregory G. Schwartz, Philippe Gabriel Steg
Journal: Circulation (2019)

Lowering of atherogenic lipoproteins, including low-density lipoprotein cholesterol (LDL-C), reduces the risk of ischemic stroke. However, concerns have been raised about very low LDL-C levels and a potential increased risk of hemorrhagic stroke. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, despite intensive statin therapy, targeting LDL-C levels of 25 to 50 mg/dL and avoiding sustained LDL-C <15 mg/dL. This prespecified analysis was designed to assess the effect of alirocumab on ischemic and hemorrhagic stroke. We hypothesized that for patients treated with alirocumab there would be a reduction in risk of ischemic stroke without increasing hemorrhagic stroke, irrespective of baseline LDL-C and of history of cerebrovascular disease. Patients were randomized to alirocumab or placebo 1 to 12 months after acute coronary syndrome. The risk of nonfatal or fatal ischemic or hemorrhagic stroke was evaluated, stratified by baseline LDL-C concentration and history of cerebrovascular disease. A potential association of very low achieved LDL-C with alirocumab treatment at month 4 and subsequent hemorrhagic stroke was assessed. Median follow-up was 2.8 years. In total, 263 ischemic and 33 hemorrhagic strokes occurred. Alirocumab reduced the risk of any stroke (HR, 0.72 [95% CI, 0.57-0.91]) and ischemic stroke (HR, 0.73 [95% CI, 0.57-0.93]) without increasing hemorrhagic stroke (HR, 0.83 [95% CI, 0.42-1.65]). In total, 7164 (37.9%), 6128 (32.4%), and 5629 (29.7%) patients had a baseline LDL-C of <80, 80 to 100, and >100 mg/dL, respectively. The treatment effect on stroke appeared numerically greater for patients with higher baseline LDL-C, but there was no formal evidence of heterogeneity (Pinteraction=0.31). The effect of alirocumab on stroke was similar among 944 patients (5.0%) with a history of previous cerebrovascular disease and among those without a history of cerebrovascular disease (Pinteraction=0.37). There was no apparent adverse relation between lower achieved LDL-C and incidence of hemorrhagic stroke in the alirocumab group. In patients with recent acute coronary syndrome and dyslipidemia despite intensive statin therapy, alirocumab decreased the risk of stroke, irrespective of baseline LDL-C and history of cerebrovascular disease, over a median follow-up of 2.8 years. Furthermore, risk of hemorrhagic stroke did not depend on achieved LDL-C levels within the alirocumab group. URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402.